propafenone has been researched along with Heart Failure in 12 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propafenone is an effective drug for the management of ventricular tachyarrhythmias, and may be used in patients with impaired left ventricular function." | 5.27 | Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. ( Abate, D; Allen, BJ; Brodsky, MA; Henry, WL, 1985) |
| "In-hospital administration of flecainide and propafenone in a single oral loading dose has been shown to be effective and superior to placebo in terminating atrial fibrillation." | 5.11 | Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. ( Alboni, P; Baldi, N; Baroffio, R; Botto, GL; Calzolari, M; Gaggioli, G; Gianfranchi, L; Luzi, M; Marchi, P; Russo, V; Solano, A, 2004) |
| " The abilities of TAEA and ISQ-1 to terminate AF, with comparison to the rapidly activating component of delayed rectifier potassium current blocker (+)-N-[1'-(6-cyano-1,2,3,4-tetrahydro-2(R)-naphthalenyl)-3,4-dihydro-4(R)-hydroxyspiro(2H-1-benzopyran-2,4'-piperidin)-6-yl]methanesulfonamide] monohydrochloride (MK-499) and the class IC 1-[2-[2-hydroxy-3-(propylamino)-propoxy]phenyl]-3-phenyl-1-propanone (propafenone), were assessed in conscious dogs with heart failure and inducible AF (entry criterion)." | 3.74 | Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure. ( Beshore, DC; Dinsmore, CJ; Kiss, L; Liverton, NJ; Lynch, JJ; McIntyre, CJ; Regan, CP; Stump, GL, 2008) |
| "The incidence of drug-induced congestive heart failure with several newer antiarrhythmic agents including encainide, ethmozine, lorcainide, mexiletine, propafenone and tocainide was determined in a group of 407 patients who underwent 1,133 drug tests." | 3.67 | Congestive heart failure induced by six of the newer antiarrhythmic drugs. ( Lampert, S; Lown, B; Podrid, PJ; Ravid, S, 1989) |
| "Propafenone is an effective drug for preventing supraventricular tachyarrhythmia, but the incidence of side effects during longterm therapy in patients with such arrhythmias has not been adequately reported." | 2.68 | Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. ( Anderson, JL; Podrid, PJ, 1996) |
| "Amiodarone has been demonstrated to be more efficacious than propafenone or sotalol in the Canadian Trial of Atrial Fibrillation." | 2.42 | Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. ( Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL, 2003) |
| "Antiarrhythmic drugs may induce congestive heart failure in patients with malignant ventricular arrhythmias and depressed left ventricular (LV) function." | 1.28 | Changes in cardiac output determined by continuous-wave Doppler echocardiography during propafenone or mexiletine drug testing. ( Lampert, S; Lange, H; Lown, B; Sutton, MS, 1990) |
| "The effects of orally administered propafenone on ejection fraction (EF) determined by radionuclide angiography were studied in 2 groups of patients receiving different dosing regimens." | 1.27 | Effect of propafenone on left ventricular ejection fraction. ( Baker, BJ; de Soyza, ND; Dinh, H; Franciosa, JA; Kroskey, D; Murphy, ML, 1984) |
| "Propafenone is an effective drug for the management of ventricular tachyarrhythmias, and may be used in patients with impaired left ventricular function." | 1.27 | Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. ( Abate, D; Allen, BJ; Brodsky, MA; Henry, WL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wybraniec, MT | 1 |
| Kampka, Z | 1 |
| Mizia-Stec, K | 1 |
| Lip, GY | 1 |
| Fauchier, L | 1 |
| Freedman, SB | 1 |
| Van Gelder, I | 1 |
| Natale, A | 1 |
| Gianni, C | 1 |
| Nattel, S | 1 |
| Potpara, T | 1 |
| Rienstra, M | 1 |
| Tse, HF | 1 |
| Lane, DA | 1 |
| Naccarelli, GV | 1 |
| Wolbrette, DL | 1 |
| Khan, M | 1 |
| Bhatta, L | 1 |
| Hynes, J | 1 |
| Samii, S | 1 |
| Luck, J | 1 |
| Alboni, P | 1 |
| Botto, GL | 1 |
| Baldi, N | 1 |
| Luzi, M | 1 |
| Russo, V | 1 |
| Gianfranchi, L | 1 |
| Marchi, P | 1 |
| Calzolari, M | 1 |
| Solano, A | 1 |
| Baroffio, R | 1 |
| Gaggioli, G | 1 |
| Regan, CP | 1 |
| Kiss, L | 1 |
| Stump, GL | 1 |
| McIntyre, CJ | 1 |
| Beshore, DC | 1 |
| Liverton, NJ | 1 |
| Dinsmore, CJ | 1 |
| Lynch, JJ | 1 |
| Baker, BJ | 1 |
| Dinh, H | 1 |
| Kroskey, D | 1 |
| de Soyza, ND | 1 |
| Murphy, ML | 1 |
| Franciosa, JA | 1 |
| Podrid, PJ | 2 |
| Anderson, JL | 1 |
| SoRelle, R | 1 |
| Lange, H | 1 |
| Lampert, S | 2 |
| Sutton, MS | 1 |
| Lown, B | 2 |
| Ravid, S | 1 |
| Sbirrazzuoli, V | 1 |
| Lapalus, P | 1 |
| Brodsky, MA | 1 |
| Allen, BJ | 1 |
| Abate, D | 1 |
| Henry, WL | 1 |
3 reviews available for propafenone and Heart Failure
| Article | Year |
|---|---|
Pharmacological cardioversion of atrial fibrillation: practical considerations.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Heart Diseases; Heart Failure; H | 2023 |
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Tria | 2003 |
2 trials available for propafenone and Heart Failure
| Article | Year |
|---|---|
Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.
Topics: Administration, Oral; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibrillation; Feasibility Stud | 2004 |
Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial | 1996 |
7 other studies available for propafenone and Heart Failure
| Article | Year |
|---|---|
Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzopyrans; Cell Line; Dogs; Female; Heart At | 2008 |
Effect of propafenone on left ventricular ejection fraction.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Output; Digoxin; Heart; Heart Failure; Humans; Male; Middle Ag | 1984 |
Late-breaking clinical trials at the American Heart Association's scientific sessions 2001.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Coronary Artery Bypass; Coron | 2001 |
Changes in cardiac output determined by continuous-wave Doppler echocardiography during propafenone or mexiletine drug testing.
Topics: Cardiac Output; Depression, Chemical; Echocardiography, Doppler; Female; Heart Failure; Humans; Male | 1990 |
Congestive heart failure induced by six of the newer antiarrhythmic drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Anti-Arrhythmia Agents; Benzeneacetamides; Enc | 1989 |
Human lymphocyte and myocardial beta-adrenoceptors: up and down regulation.
Topics: Down-Regulation; Female; Heart Failure; Humans; Lymphocytes; Male; Middle Aged; Myocardium; Propafen | 1989 |
Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Electrophysiology; E | 1985 |